Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cefazolin + metronidazole + lidocaine + epinephrine** is a multi-drug formulation administered as a tumescent solution, primarily for the prevention of surgical site infections (SSIs) during procedures at high infection risk, such as open colorectal surgery. The antibiotics, **cefazolin** (a first-generation cephalosporin) and **metronidazole** (a nitroimidazole antibiotic), provide broad-spectrum antimicrobial prophylaxis against aerobic and anaerobic bacteria[1][3]. **Lidocaine**, an amide local anesthetic, prevents perioperative pain through sodium channel blockade, while **epinephrine** serves as a local vasoconstrictor to prolong anesthetic action and reduce systemic absorption of lidocaine, improving local drug retention[1][7]. This combination is delivered via **tumescent anesthesia antibiotic delivery (TAAD)**, in which all four components are diluted in saline (with sodium bicarbonate), and infiltrated subcutaneously. This technique achieves high interstitial concentrations of antibiotics, long-lasting anesthesia, and significant local hemostasis[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefazolin + metronidazole + lidocaine + epinephrine.